TNBC: Avatar: Feasibility/Pilot Study of Genomics-Guided Therapeutic Drug Selection for Triple Negative Breast Cancer (TNBC) Using a Patient-Derived Mouse Xenograft
Aims: The purpose of this study is to see if tumor genetics, PDX mouse model and cell lines can be helpful in predictions which treatment would be most effective for an individual breast cancer pateint. In addition, if your cancer returns, doctors may be able to use their information learned from treating the PDX mouse to guide the choice of treatment for your cancer.
Diagnosis: Triple negative breast cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH15-066
Sponsor: The Jackson Laboratory
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes 

Novartis: CRQAD001JUS226: A Phase II, Single Arm Study of the Use of Steroid-Based Moutwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treateted with Everolimus Plus Exemestane
Aims: The purpse of this study is to evaluate the effectiveness of an investigational sterioid-based mouth wash, and to see if it can help prevent or reduce the severity and duration of oral stomatitis, a common side effect of Everolimus.
Diagnosis: Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH15-063
Sponsor: Novartis Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

LATTE: Long Term Anastrozole versus Tamoxifen Treatment Effects
Aims: The LATTE study is an extension study to the now closed ATAC trial that took place 10 years ago. LATTE aims to collect long term follow-up information since the conclusion of the ATAC study and for at least another 5 years.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH13-352
Sponsor: American Cancer Society, Inc/ Queen Mary University of London
Contact: Interested patients should contact research coordinator Nancy Haefling at 847.503.1188
Open to Enrollment: Yes 

UC13-1-000: Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Presistent Epithelial Ovarian Cancer
Aims: The purpse of this study is to find the safest dose of mifepristone when given with standard chemotherapy using carboplatin and gemcitabine. The study will look at the side effects, how your body processes the drugs, and the effects of the drug combination on your body and your cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-248
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

AbbVie M12-914: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer 
Aims: The main purpose of the study is to determine if veliparib in combination with carboplatin and paclitaxel improves the efficacy of chemotherapy alone in participants with a BRCA1 or BRCA2 mutation and HER2-negative metastatic or locally advanced breast cancer. Carboplatin and paclitaxel are chemotherapy drugs are widely used as a treatment for advanced or metastatic (spread to/from other areas) breast cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-199
Sponsor: AbbVie
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Aims: The purpse of this study is to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug Administration (FDA) of the United States for use after surgery for postmenopausal women with estrogen receptor positive breast cancer.
Diagnosis: Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-308
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olparib Versus Placebo as Adjuvant Treatement in patients with Germline BRAC1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definiteive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Aims: The purpse of this study is to compare the addition of olaparib after the usual care of chemotherapy, surgery, and radiation for your type of cancer. In this study, you will get either olaparib or placebo.
Diagnosis: BreastGermline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer
Principal Investigator: Douglas Merkel, MD
IRB Approval Number: EH14-400
Sponsor: NSABP
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

× Alternate Text